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Background: Traditional assessment of drug-induced hepatotoxicity includes morphological examination of the
liver and evaluation of liver enzyme activity in serum. The objective of the study was to determine the origin of
drug-related elevation in serum alanine aminotransferase (ALT) activity in the absence of morphologic changes in
the liver by utilizing molecular and immunohistochemical techniques.
Methods: Sixteen female Sprague-Dawley rats were divided into 2 groups (control and treated, n = 4 per group)
and treated rats were dosed orally twice daily (400 mg/kg/day) for 7 days with a VEGFR-2 compound (AG28262),
which in a previous study caused ALT elevation without morphological changes. Serum of both treated and
control animals were evaluated on day 3 of treatment and at day 8. Three separate liver lobes (caudate, right
medial, and left lateral) were examined for determination of ALT tissue activity, ALT gene expression and
morphological changes.
Results: ALT activity was significantly (p < 0.01) elevated on day 3 and further increased on day 8. Histologic
changes or increase in TUNEL and caspase3 positive cells were not observed in the liver lobes examined. ALT gene
expression in the caudate lobe was significantly up-regulated by 63%. ALT expression in the left lateral lobe was
not significantly affected. Statistically significant increased liver ALT enzymatic activity occurred in the caudate
(96%) and right medial (41%) lobes but not in the left lateral lobe.
Conclusions: AG28262, a VEFG-r2 inhibitor, causes an increase in serum ALT, due in part to both gene up-
regulation. Differences between liver lobes may be attributable to differential distribution of blood from portal
circulation. Incorporation of molecular data, such as gene and protein expression, and sampling multiple liver lobes
may shed mechanistic insight to the evaluation of hepatotoxicity.
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Background
The liver provides many essential functions such as reg-
ulation of amino acids and glucose in the blood, produc-
tion of bile, and the biotransformation of toxins and
drugs. The liver is the first organ to encounter nutrients,
drugs and toxins absorbed into the enteric system
through the portal vein [1]. Many of the toxins, which
pass through the liver are metabolized and excreted
using numerous metabolic pathways involving specia-
lized enzymes specifically for detoxification. Because of
the liver’s important role in biotransformation of drugs
and toxins, drug-induced hepatotoxicity is a major con-
cern in drug development and chronic drug therapy.
A common, liver specific biomarker used to evaluate
acute hepatotoxicity is Alanine aminotransferase (ALT).
ALT is a cytosolic enzyme found in hepatocytes, and is
frequently examined in patients undergoing chronic
drug therapy or in the pre-clinical stages of drug devel-
opment to monitor the status of the liver. Serum con-
centrations of ALT rise in response to direct damage to
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cell metabolism [2]. ALT is commonly evaluated in con-
junction with aspartate aminotransferase (AST), a non-
specific enzyme found in the liver, as well as histologic
morphology of the liver [3]. Drug related discrepancies
have been identified where elevation in serum ALT is
detected without a hepatic morphologic correlation. An
example of this includes isoniazid, a compound that
induces an elevation in serum ALT and AST activity
without directly causing hepatic damage [3]. Another
example, diclofenac, a non-steroidal anti-inflammatory
drug also has been reported to elevate serum amino-
transferase activity; however some patients progressed to
consequentially develop liver disease [4].
Elucidating the drug-related mechanism which ele-
vates serum ALT activity is crucial to better understand
the potential for consequent hepatic disease. This study
investigates potential mechanisms resulting in elevated
serum ALT activity using rats treated with a VEGFR-2
inhibitor (AG28262). Vascular endothelial growth factor
(VEGF) induces angiogenesis and is a potent mediator
of vascular permeability. The biological effects of VEGF
are mediated by two tyrosine kinase receptors, Flt-1
(VEGFR-1) and KDR (VEGFR-2). Inhibition of VEGF
activity may be beneficial in the treatment of conditions
involving angiogenesis [5]. Since the liver is a heteroge-
neous tissue and lobe variation has been reported in
hepatotoxicity [6], three liver lobes (caudate, right med-
ial and left lateral) were selected for examination using
morphological evaluation and molecular techniques.
Methods
Animals
Eight female Sprague-Dawley rats (Charles River Labora-
tories, Raleigh, NC) weighing between 220-250 grams
were used in the study. Animals were allowed to accli-
mate for one-week prior to use. All animals were given
food and water ad-libitum, and housed under a 12-hour
light/12-hour dark cycle.
Institutional compliance statement
Animals were housed in facilities at Pfizer (La Jolla, CA,
USA) that are approved by the American Association
for the Accreditation of Laboratory Animal Care. All
protocols were approved by the Pfizer Global Research
and Development Institutional Animal Care and Use
Committee.
Study design
Animals were assigned to a control (0.5% carboxy-
methylcellulose) and a treated group (400 mg/kg/day of
AG028262) and were dosed orally twice daily for seven
consecutive days (n = 4 per group). Clinical observation
was performed daily. Body weights were taken on days
1, 6, and 8. Clinical chemistry and hematological sam-
ples were collected on day 8 via blood collection from
the abdominal vena cava. In addition, clinical chemistry
was evaluated on day 3 during treatment via tail vein
collection. ALT, ALP and AST enzymatic activity and
other biochemical tests were performed with a Hitachi
911 chemical analyzer using a standardized method. A
necropsy was conducted on each rat on day 8 and gross
observations were recorded. The left lateral, right medial
and caudate lobes of the liver were collected, weighed,
and examined for gross lesions. Liver lobes were
selected based upon the differential distribution of the
portal hemodynamics through the liver lobes [7]. Tissue
for RNA analysis was collected in RNA later (Qiagen,
Valencia, CA) and directly transferred to liquid nitrogen.
Tissue for protein quantification was directly transferred
to liquid nitrogen for freezing. The remaining tissues
were fixed in 10% neutral buffered formalin and sub-
mitted to histology for processing and staining with
H&E, caspase 3 and TUNEL method.
RNA isolation and reverse transcription
Tissues were homogenized by an ultra turrax homogeni-
zer (IKA Works, Wilmington, NC) and RNA extracted
using the RNeasy Lipid tissue midi kit) (Qiagen). Oligo-
dT primed reverse transcription was carried out with 1
μg total RNA using the Retroscript kit (Ambion; Austin,
TX). For detecting gene expression of alanine amino-
transferase (ALT), the following primers were used: 5’-
TTCAAGCAGAGAGACAGGAG-3’ and 5’-TGAGG-
GAAGGAATACATGG-3.’ The primers for b-actin,
used as a reference gene to normalize expression levels
between samples, were: 5’- CTCACTGTCCACCTTC-
CAG-3’ and 5’- AACGCAGCTCAGTAACAGTC-3.’ To
amplify and quantitate cDNA, 1 μl of cDNA generated
by reverse transcription was added to 19 μl of PCR mix
containing SYBER green PCR master mix (Qiagen), 2
μM primers, and RNAse free water. The reaction was
performed by Light Cycler (Roche Diagnostics, Indiana-
polis IN). PCR cycle settings for ALT were set 94°C for
15 s, followed by 52°C for 20 s, and 72°C for 30 s for 50
cycles. For b-actin reactions the annealing temperature
was changed to 55°C. Light Cycler software version 3.5
(Roche) was used for data analysis. Standards generated
from traditional PCR reactions were included in each
amplification run to generate a standard curve off of
which samples were quantified and expressed as a rela-
tive value. Values were then normalized to the reference
gene to generate gene expression results expressed as a
relative ratio.
Cleaved caspase 3 and TUNEL
Samples of the caudate, right medial, and left lateral
liver lobes were paraffin-embedded, serially sectioned at
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and stained for markers of apoptosis. Deparaffinization
and antigen retrieval were performed in 1X Reveal solu-
tion using a Decloaking Chamber (Biocare Medical,
Walnut Creek, CA). Endogenous peroxidase activity was
blocked using 3% hydrogen peroxide (Sigma, St. Louis,
MO). The Dako Autostainer (Dako-Cytomation, Carpin-
teria, CA) was programmed to complete the immuno-
histochemistry staining for caspase 3. Protein Blocking
Serum (Dako) was used first to reduce background
staining. Caspase-3 polyclonal antibody (1:200 dilution;
Cell Signaling, Beverly, MA) was the primary antibody
directed against cleaved caspase-3. The negative control
consisted of replacing the primary antibody with non-
specific Rabbit IgG antibody (Dako). Biotinylated anti-
rabbit immunoglobulin (1:200 diluted in Dako Antibody
Diluent) was used as the secondary antibody. Antibody
binding was visualized using streptavidin peroxidase
(1:200 diluted in antibody diluent) and DAB+ chromo-
gen followed by hematoxylin counterstain. Terminal
deoxynucleotidyl transferase (Tdt)-mediated dUTP nick-
end labeling (TUNEL) was performed using the Dead-
End Colorimetric TUNEL system (Promega, Madison,
WI). Briefly, sections were rehydrated in decreasing con-
centration of ethanol followed by a wash in 0.85% NaCl
(Sigma) for 5 minutes. After a final wash in PBS, sec-
tions were fixed in 10% formalin in PBS (Richard Allen
Scientific, Kalamazoo, MI) for 15 minutes. To help per-
meabilize tissue, sections were incubated in Proteinase
K (Dako) for 20 minutes. The remaining steps including
equilibration and end labeling reaction were followed
per manufacturer’s protocol (Promega). Apoptotic cells
were detected after incubation in DAB chromogen (Invi-
trogen; Carlsbad, CA) for 2.5 minutes followed with
hematoxylin counterstaining (Dako). All slides were
cover slipped using permanent mounting medium
(Richard Allen Scientific).
Crude liver ALT quantification
Liver tissue (50 mg of each lobe) was weighed and
homogenized using the ultra turrax homogenizer in 1
mL buffer (100 mM phosphate buffer at pH 7.4, 0.25 M
Sucrose, 0.01 mM EDTA), complete protease inhibitor
cocktail tablets (Roche), and 2 mM PMSF. Samples were
centrifuged at 2500 g, 4°C for 15 minutes. ALT enzy-
matic activity in the supernatant was quantified (U/L)
using the Hitachi 911 Analyzer (Roche) at 37°C. Pig
heart ALT (Roche) of known enzymatic activity was
used to verify the performance of the Hitachi 911 in
measuring enzymatic activity in crude tissue.
Morphometry
Chromavision (Chromavision Medical Systems, San Juan
Capistrano, CA) was utilized for morphometrical
analysis of caspase 3 and TUNEL stained slides. Quanti-
fication was done by a pre-programmed logarithm direc-
ted specifically in the identification of caspase 3 and
TUNEL stained slides.
Statistical analysis
Statistical analysis was done by 2-sample equal variance
t-Test. Significance was set at p ≤ 0.01.
Results
In-vivo observations
Significant changes in body weights and clinical signs
were not observed for the 7-day duration of the study.
There were no unscheduled deaths in the study or sig-
nificant changes found during gross examination. Differ-
ences in liver weight between controls and treated
animals were not observed.
Histology
No significant morphologic changes were observed in
the livers of compound-treated or control rats (data not
shown). Differences between liver lobes were not
detected.
Caspase 3 and TUNEL
Few caspase 3 and TUNEL positive cells were seen in
the livers of both treated and control rats. No significant
statistical differences between these groups were
detected using morphometry.
Clinical pathology
ALT, ALP, and AST activity was measured in the serum
of compound-treated and control rats and results are
presented in Table 1. On day 3 of treatment, AG28262
induced a statistically significant increase in serum ALT
activity (63%; p ≤ 0.01) compared to controls. On day 8,
ALT activity progressively increased by approximately 2-
fold compared to the control group, a statistically signif-
icant difference (p ≤ 0.01). There was a progressive
increase in serum ALP activity from day 3 to day 8 in
treated animals, and the increase in treated rats at day 8
was statistically significant compared to controls. Serum
Table 1 Effect of AG28262, a VEGR-2 inhibitor, on serum
ALT, ALP and AST enzymatic activity in treated and
control rats
Group Day sampled ALT (U/L) ALP (U/L) AST (U/L)
Control 3 53 ± 2 175 ± 15 99 ± 3
400 mg/kg 3 82 ± 7 * 197 ± 16 111 ± 1
Control 8 55 ± 4 153 ± 12 89 ± 2
400 mg/kg 8 118 ± 19* 209 ± 15* 150 ± 40
Values expressed as mean U/L ± SEM.
*Statistically significant (p ≤ 0.01).
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8 compared to the control rats but the increase was not
statistically significant due to individual variability.
AG28262-induced effect on ALT gene expression
In the right medial lobe, AG28262 treatment resulted in
a 49% increase ALT gene expression compared to the
control animals on day 8 (Figure 1). Relative expression
of ALT in the left lateral liver lobe at day 8 of termina-
tion was not significantly different from the control
group (Figure 2). The caudate lobe had a statistically
significant (p ≤ 0.01) increase in ALT gene expression
of 63% in comparison to the control group (Figure 3).
AG28262-induced effect on crude liver ALT enzymatic
activity
Both the right medial and caudate lobes demonstrated a
statistical increase in ALT enzymatic activity when com-
pared to the control with 41% (p ≤ 0.01) and 96% (p ≤
0.01) increase respectively (Figures 1 and 3). Enzymatic
ALT activity in the left lateral lobe was elevated by 29%
in comparison to the control (Figure 2), but the differ-
ence was not statistically significant.
Discussion
Differences in drug effects between liver lobes should be
considered in toxicology evaluation of compounds. Tra-
ditional thinking regarding drug-induced hepatotoxicity
commonly correlates elevated serum ALT with direct
hepatocellular damage. However, instances of elevated
serum ALT in the absence of microscopic evidence of
hepatocellular injury do occur with some xenobiotics.
This investigation was conducted to understand the
ALT elevation observed with AG28262, a VEGFR-2
inhibitor, in treated rats in the absence of morphological
changes in the liver. The results of this investigation
suggests that the source of increased serum ALT in
AG28262 treated rats is due to an increase in gene
expression rather than leakage as a result of overt hepa-
tocellular necrosis. This study also showed a regional
specific effect on ALT mRNA and protein levels within
the various lobes of the liver.
In an effort to rule out drug-induced hepatocellular
apoptosis as a potential cause of increases in serum
ALT activity, caspase 3 immunohistochemistry and
TUNEL assays were used. Both assays demonstrated
equivalent positive staining in the compound-treated
and control rats. This information suggests that eleva-
tion in serum ALT was not due to hepatocellular apop-
tosis, but to an alternative mechanism. The results
obtained from caspase 3 and TUNEL assays further sup-
ported the lack of morphologic hepatic changes.
AG28262 treatment resulted in increased activity of
ALT, AST, and ALP suggesting that AG28262 induces
hepatic injury. Clinical chemistry data demonstrated a
statistically significant increase in serum ALT, ALP
activities, and increased (but not statistically signifi-
cant) AST activity on day 8. Serum AST activity on
day 8 showed individual variability within the com-
pound-treated group; however there was still a remark-
able elevation when compared to control animals.
ALT, AST, and ALP are all enzymes found in the liver
and are commonly used in conjunction to evaluate
hepatic changes [8]. Despite these elevations in liver
enzyme activity there were not morphological corre-









































Figure 1 Effect of AG28262, a VEGR-2 inhibitor, on ALT gene expression and enzymatic activity in the right medial liver lobe. Relative
gene expression values are reported as mRNA ALT/mRNA beta-actin. * Statistically significant (p < 0.01).
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may contribute to the elevation in serum ALT in this
study. However, creatine kinase serum enzymatic activ-
ity, a specific marker for muscle or kidney damage
[9-12], was not significantly changed in this study. Mor-
phological changes were not observed in these tissues
and further studies were not pursued at the time.
Real time PCR was used to measure changes in ALT
gene expression between the treated and control ani-
mals. Using beta-actin for normalization, AG28262 eli-
cited an increased in hepatic ALT mRNA levels.
Additionally, regional differences among the lobes of the
liver were observed in AG28262 treated rats. The largest
increase in ALT mRNA was in the caudate lobe, fol-
lowed by the right medial, and lastly the left lateral lobe.
The caudate lobe showed a 63% significant increase in
gene expression comparison to the control. Gene
expression in the treated right medial lobe was also
increased by 49%; however, individual variability within
the group prevented the result from reaching statistical
significance. AG28262 induced a slight change in gene








































Figure 2 Effect of AG28262, a VEGR-2 inhibitor, on ALT gene expression and enzymatic activity in the left lateral liver lobe. Relative










































Figure 3 Effect of AG28262, a VEGR-2 inhibitor, on ALT gene expression and enzymatic activity in the caudate liver lobe. Relative gene
expression values are reported as mRNA ALT/mRNA beta-actin.
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activity in the lobes and ALT gene expression was iden-
tified. The caudate lobe, which had significant elevations
in gene expression, also demonstrated a significant ele-
vation in ALT enzymatic activity. The right medial lobe
also showed a significant increase in ALT enzymatic
activity, which correlated with elevation in ALT gene
expression. The left lateral lobe had a slight increase in
ALT concentration, which may be due to only a minor
increase in gene expression. These data suggest that the
effect of AG28262 is targeted towards ALT gene regula-
tion resulting in increased synthesis of ALT enzyme in
the hepatocytes. The source of serum ALT appears to
originate from the liver, but more specifically the cau-
date and right medial liver lobes.
The variability on ALT activity between the liver
lobes confirms the heterogeneity of the liver and war-
rants the investigation of multiple liver lobes in future
drug toxicity studies. Previous hepatotoxicity studies
involving copper and acetaminophen have supported
the idea of lobular heterogeneity [13,14]. Both copper
and acetominophen have been studied extensively and
it has been shown that effect of both toxins is differen-
tial in nature. The distributional effect of copper, for
example is thought to reflect the site of gastrointestinal
absorption and portal streamlining into the liver [14].
Other studies have indicated that the right liver lobe is
predisposed to the effects of drugs and toxins based on
favored portal streamlining to the right portal branch
which supplies the right side of the liver [6]. The
effects of AG28262 in this stu d yw e r ec l e a r l yc o n c e n -
trated in the right medial and caudate liver lobes sug-
gesting that the compound may preferentially be
transported through the right portal branch into the
right side of the liver. The caudate lobe of the liver has
been previously shown to receive blood supply from
the right and left branches of the portal vein [7].
Insight on the potential distribution of drugs and tox-
ins may help in understanding the potential localiza-
tion of hepatic diseases and carcinomas within the
liver. Understanding these regional effects is critical in
the interpretation of data that captures endpoints from
specific liver lobes (eg. toxicogenomics).
The combination of ALT gene up-regulation and a
lack of morphologic change support the importance of
utilizing toxicogenomics in evaluating potential drug
related changes. Toxicogenomics is a relatively new tool
incorporating genomics and proteomics and can prove
useful in short-term drug toxicity studies because gene
and protein changes can be detected before drug
induced morphologic changes [15]. A study involving
acetaminophen toxicity demonstrated that gene expres-
sion profiling serves as an important indicator of poten-
tial toxic effects in the absence of apparent toxicity [16].
Collection of samples for gene expression analysis is not
done routinely in exploratory toxicology studies. Such
practice may prove useful so that the mechanisms of
findings such as those reported in this study can be
explored. In this study genomics proved useful in identi-
fying the cause and source of serum ALT elevation. It is
still unknown whether the chronic effect of AG28262
will result in morphologic changes or if the compound
will independently alter the intrinsic regulation of ALT
gene expression and synthesis. Further investigation is
necessary to determine if effects of the compound are
occurring ultrastructurally, biochemically, or if there is
involvement of a transcription factor, which may be
altering gene expression.
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